Torthaí cuardaigh - Werner Scheithauer
- 1 - 20 toradh as 54 á dtaispeáint
- Téigh chuig an gcéad leathanach eile
-
1
Clinical trials of agents that reverse multidrug resistance. A literature review de réir Markus Raderer, Werner Scheithauer
Foilsithe / Cruthaithe 1993Revisão -
2
Ondansetron for Pruritus Due to Cholestasis de réir Markus Raderer, Christian A. Müller, Werner Scheithauer
Foilsithe / Cruthaithe 1994Carta -
3
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside de réir Burghardt Wittig, Manuel Schmidt, Werner Scheithauer, Hans‐Joachim Schmoll
Foilsithe / Cruthaithe 2014Revisão -
4
HER 2/neu protein expression in colorectal cancer de réir B. Schuell, Thomas Gruenberger, Werner Scheithauer, Ch. Zielinski, Fritz Wrba
Foilsithe / Cruthaithe 2006Artigo -
5
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. de réir Werner Scheithauer, Harald Rosén, Gabriela Kornek, Christian Sebesta, D. Depisch
Foilsithe / Cruthaithe 1993Artigo -
6
Answering Patients' Needs: Oral Alternatives to Intravenous Therapy de réir Markus Borner, Werner Scheithauer, Chris Twelves, Jean A. Maroun, H. Wilke
Foilsithe / Cruthaithe 2001Revisão -
7
A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid de réir Markus Kieler, Matthias Unseld, Daniela Bianconi, Werner Scheithauer, Gerald W. Prager
Foilsithe / Cruthaithe 2019Artigo -
8
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases de réir Birgit Gruenberger, Werner Scheithauer, Robert Punzengruber, Christoph Zielinski, Dietmar Tamandl, Thomas Gruenberger
Foilsithe / Cruthaithe 2008Artigo -
9
Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer de réir B. Gruenberger, Dietmar Tamandl, Johannes Schueller, Werner Scheithauer, Christoph Zielinski, Friedrich Herbst, Thomas Gruenberger
Foilsithe / Cruthaithe 2008Artigo -
10
Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial de réir Gabriela Kornek, B. Schuell, Friedrich Laengle, Thomas Gruenberger, M. Penz, K. Karall, D. Depisch, Fritz Lang, Werner Scheithauer
Foilsithe / Cruthaithe 2004Artigo -
11
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer de réir Gerald W. Prager, Kira Braemswig, Alexandra Martel, Matthias Unseld, Georg Heinze, Thomas Brodowicz, Werner Scheithauer, Gabriela Kornek, Christoph Zielinski
Foilsithe / Cruthaithe 2014Artigo -
12
Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study de réir Boris Dickmann, Jonas Ahlbrecht, Cihan Ay, Daniela Dunkler, J. Thaler, Werner Scheithauer, Peter Quehenberger, C. C. Zielinski, Ingrid Pabinger
Foilsithe / Cruthaithe 2013Artigo -
13
Thrombosis risk and survival in cancer patients with elevated C‐reactive protein de réir R. Kanz, Thomas Vukovich, Rainer Vormittag, Daniela Dunkler, Cihan Ay, J. Thaler, Johanna Haselböck, Werner Scheithauer, Christoph Zielinski, Ingrid Pabinger
Foilsithe / Cruthaithe 2010Artigo -
14
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer de réir M. Penz, Gabriela Kornek, Markus Raderer, H. Ulrich-Pur, Wolfgang Fiebiger, A. Lenauer, D. Depisch, G. Krauss, Bruno Schneeweiß, Werner Scheithauer
Foilsithe / Cruthaithe 2001Artigo -
15
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemothera... de réir Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera‐Knorrenschild, D. Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer
Foilsithe / Cruthaithe 2014Artigo -
16
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results de réir J Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Karen Rittweger, Frank Gilberg, Leonard B. Saltz
Foilsithe / Cruthaithe 2011Artigo -
17
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of... de réir Chris Twelves, Werner Scheithauer, J. McKendrick, Jean‐François Seitz, Guy van Hazel, A. Wong, Eduardo Díaz‐Rubio, Frank Gilberg, J Cassidy
Foilsithe / Cruthaithe 2011Artigo -
18
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma de réir H. Ulrich-Pur, Markus Raderer, Gabriela Kornek, B. Schüll, Katharina Schmid, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Fritz Lang, Werner Scheithauer
Foilsithe / Cruthaithe 2003Artigo -
19
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial de réir Werner Scheithauer, B. Schüll, H. Ulrich-Pur, Katharina Schmid, Markus Raderer, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Friedrich Lang, Gabriela Kornek
Foilsithe / Cruthaithe 2002Artigo -
20
Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors de réir Irene Virgolini, Markus Raderer, Amir Kurtaran, P. Angelberger, S. Banyai, Qiong Yang, Shuren Li, Martin Banyai, Johann Pidlich, Bruno Niederle, Werner Scheithauer, Peter Valent
Foilsithe / Cruthaithe 1994Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Internal medicine
Medicine
Cancer
Oncology
Colorectal cancer
Chemotherapy
Surgery
Gastroenterology
Confidence interval
Hazard ratio
Capecitabine
Clinical endpoint
Gemcitabine
Fluorouracil
Pancreatic cancer
Randomized controlled trial
Bevacizumab
Environmental health
Oxaliplatin
Population
Cetuximab
Clinical trial
Irinotecan
Folinic acid
Pathology
Neutropenia
Regimen
Adverse effect
FOLFIRI
Intensive care medicine